Similar strategies based on blocking tumor-associated macrophages similar to the M2 immunosuppressive phenotype by blocking colony-stimulating factor 1 receptor using AMG 820, an antibody directed against human colony-stimulating factor 1 receptor, in combination with pembrolizumab showed preliminary evidence of activity [clinical benefit rate (irPR and irSD) of 36%] (160). The gene discussed is CSF1R; the disease is neoplasm.